topaz-1: the addition of durvalumab to chemotherpay for the treatment of btc in the 1st-line setting
Published 2 years ago • 1K plays • Length 3:17Download video MP4
Download video MP3
Similar videos
-
2:51
topaz-1: 3-year survival, elts & safety of durvalumab and chemotherapy in btc
-
5:45
subgroup analysis of the topaz-1 study by primary tumor location
-
26:50
ac22 - topaz-1 trial in biliary tract cancer
-
2:05
future developments in immunotherapy for treatment of biliary tract cancer
-
1:07
combining 1l chemo-immunotherapy with oleclumab in patients with advanced tnbc
-
6:04
durvalumab plus chemotherapy significantly improved os in advanced biliary tract cancer
-
1:30
begonia: durvalumab combinations in advanced tnbc
-
7:29
first-line treatment recommendations based on tmb
-
5:56
the emerging role of immunotherapy in cholangiocarcinoma
-
2:53
hudson: durvalumab combination therapies to overcome pd-l1 blockade resistance in advanced nsclc
-
0:43
double immunotherapy with durvalumab and tremelimumab versus quadruple therapy in nsclc
-
11:11
extending durvalumab maintenance to special populations
-
4:56
himalaya: tremelimumab durvalumab in unresectable hcc
-
0:33
keynote-966: pembrolizumab gem/cis vs gemc/cis alone in advanced biliary tract cancer
-
3:39
what is durvalumab’s future as a treatment option in lung cancer?
-
2:47
immunotherapy plus tkis for the treatment of crc
-
7:22
treatment landscape for cholangiocarcinoma
-
3:25
impact of radiation dose to immune cells in unresectable or stage iii nsclc in the durvalumab era
-
3:50
testing the safety and efficacy of the pd-l1 antibody durvalumab